Efruxifermin in Compensated Liver Cirrhosis Caused by MASH

In this phase IIb, randomized, placebo-controlled, double-blind trial, investigators assigned patients with MASH who had biopsy-confirmed compensated cirrhosis to receive subcutaneous efruxifermin or placebo.